Literature DB >> 33571843

A reversed phase HPLC method for the quantification of HIV gp145 glycoprotein levels from cell culture supernatants.

José A González-Feliciano1, Coral M Capó-Vélez1, Pearl Akamine1, Manuel Delgado-Vélez1, Ruth Almodóvar2, Javier Rivera2, Ignacio Pino2, Gloriner Morell2, Daniel Eichinger2, José H Rivera2, José A Lasalde-Dominicci3, Abel Baerga-Ortiz4.   

Abstract

A reversed phase high performance liquid chromatography (RP-HPLC) method was developed for the quantitative determination of recombinant HIV-1 gp145 produced in CHO-K1 cells, as measured directly from culture supernatants. Samples were diluted in 50% D-PBS and 50% PowerCHO-2 (PC2) spent medium, and resolved on a Zorbax 300SB-C8 Rapid Resolution (2.1 × 50 mm, 3.5 µm) column, fitted with a C8 guard column (Zorbax 300SB-C8, 2.1 × 12.5 mm, 5 µm), using 0.1% TFA and 2% n-propanol in LC-MS water as mobile phase A and 0.1% TFA, 70% isopropanol, and 20% acetonitrile in LC-MS water as mobile phase B. The column temperature was 80 °C, the flow rate was 0.4 mL/min and the absorbance was monitored at 280 nm. The procedures and capabilities of the method were evaluated against the criteria for linearity, limit of detection (LOD), accuracy, repeatability, and robustness as defined by the International Conference on Harmonization (ICH) 2005 Q2(R1) guidelines. Two different variants of the HIV-1 envelope protein (Env), CO6980v0c22 gp145 and SF162 gp140, were analyzed and their retention times were found to be different. The method showed good linearity (R2 = 0.9996), a lower LOD of 2.4 µg/mL, and an average recovery of 101%. The analysis includes measurements of accuracy, inter-user precision, and robustness. Overall, we present a RP-HPLC method that could be applied for the quantitation of cell culture titers for this and other variants of HIV Env following ICH guidelines.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Env; Glycoprotein; HIV vaccine; Vaccine production titer; gp145

Mesh:

Substances:

Year:  2021        PMID: 33571843      PMCID: PMC8041096          DOI: 10.1016/j.jchromb.2021.122562

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  27 in total

1.  Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates.

Authors:  L Stamatatos; M Lim; C Cheng-Mayer
Journal:  AIDS Res Hum Retroviruses       Date:  2000-07-01       Impact factor: 2.205

2.  Case study on human α1-antitrypsin: Recombinant protein titers obtained by commercial ELISA kits are inaccurate.

Authors:  Henning Gram Hansen; Helene Faustrup Kildegaard; Gyun Min Lee; Stefan Kol
Journal:  Biotechnol J       Date:  2016-11-17       Impact factor: 4.677

3.  Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.

Authors:  Lindsay Wieczorek; Shelly J Krebs; Vaniambadi Kalyanaraman; Stephen Whitney; Sodsai Tovanabutra; Carlos G Moscoso; Eric Sanders-Buell; Constance Williams; Bonnie Slike; Sebastian Molnar; Vincent Dussupt; S Munir Alam; Agnes-Laurence Chenine; Tina Tong; Edgar L Hill; Hua-Xin Liao; Michael Hoelscher; Leonard Maboko; Susan Zolla-Pazner; Barton F Haynes; Michael Pensiero; Francine McCutchan; Shawyon Malek-Salehi; R Holland Cheng; Merlin L Robb; Thomas VanCott; Nelson L Michael; Mary A Marovich; Carl R Alving; Gary R Matyas; Mangala Rao; Victoria R Polonis
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

4.  Structure-Guided Redesign Increases the Propensity of HIV Env To Generate Highly Stable Soluble Trimers.

Authors:  Javier Guenaga; Viktoriya Dubrovskaya; Natalia de Val; Shailendra K Sharma; Barbara Carrette; Andrew B Ward; Richard T Wyatt
Journal:  J Virol       Date:  2015-12-30       Impact factor: 5.103

5.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Authors:  Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Joseph Chiu; Robert Paris; Nakorn Premsri; Chawetsan Namwat; Mark de Souza; Elizabeth Adams; Michael Benenson; Sanjay Gurunathan; Jim Tartaglia; John G McNeil; Donald P Francis; Donald Stablein; Deborah L Birx; Supamit Chunsuttiwat; Chirasak Khamboonruang; Prasert Thongcharoen; Merlin L Robb; Nelson L Michael; Prayura Kunasol; Jerome H Kim
Journal:  N Engl J Med       Date:  2009-10-20       Impact factor: 91.245

6.  Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine.

Authors:  J Wintsch; C L Chaignat; D G Braun; M Jeannet; H Stalder; S Abrignani; D Montagna; F Clavijo; P Moret; J M Dayer
Journal:  J Infect Dis       Date:  1991-02       Impact factor: 5.226

Review 7.  GP120: target for neutralizing HIV-1 antibodies.

Authors:  Ralph Pantophlet; Dennis R Burton
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

Review 8.  Native-like Env trimers as a platform for HIV-1 vaccine design.

Authors:  Rogier W Sanders; John P Moore
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

9.  Rational Design of DNA-Expressed Stabilized Native-Like HIV-1 Envelope Trimers.

Authors:  Yoann Aldon; Paul F McKay; Joel Allen; Gabriel Ozorowski; Réka Felfödiné Lévai; Monica Tolazzi; Paul Rogers; Linling He; Natalia de Val; Katalin Fábián; Gabriella Scarlatti; Jiang Zhu; Andrew B Ward; Max Crispin; Robin J Shattock
Journal:  Cell Rep       Date:  2018-09-18       Impact factor: 9.423

10.  cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate.

Authors:  Antu K Dey; Albert Cupo; Gabriel Ozorowski; Vaneet K Sharma; Anna-Janina Behrens; Eden P Go; Thomas J Ketas; Anila Yasmeen; Per J Klasse; Eddy Sayeed; Heather Desaire; Max Crispin; Ian A Wilson; Rogier W Sanders; Thomas Hassell; Andrew B Ward; John P Moore
Journal:  Biotechnol Bioeng       Date:  2017-12-11       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.